Gait analysis could lead to reduced falls, injuries in people with glaucoma

NewsGuard 100/100 Score

Washington State University researchers have developed a way to carefully analyze a person's gait with sensors, an innovation that could lead to reduced falls and injuries in people with glaucoma, the second leading cause of blindness in the United States.

Led by Hassan Ghasemzadeh, assistant professor in the WSU School of Electrical Engineering and Computer Science, and graduate student Yuchao Ma, the researchers presented their gait analysis study results at the ACM Wireless Health Conference last week in Bethesda, Md.

Working with a group from the University of California, Los Angeles, they have begun clinical trials. See a video at https://www.youtube.com/watch?v=IJPbV1xb7G4.

"Glaucoma is usually diagnosed late," Ma said. "But earlier detection of gait disturbances could make a difference."

Previous studies have shown that glaucoma patients fall more often as their visual deterioration progresses. They walk more slowly, sway, bump into obstacles and have unequal step placement of their feet. However, most patients aren't diagnosed until they suffer from ocular discomfort, which usually occurs later in the disease when it's less treatable.

The researchers developed a sensing platform worn on special shoes to measure, filter and analyze gait information. The research team can detect and examine specific features of gait, such as step length, equity between feet and evenness of step. In the clinical trials, researchers are comparing the gaits of glaucoma patients and control groups.

The researchers hope to use the technology someday to diagnose the disease earlier and outside laboratory settings, adding to the current practice of imaging or a visual field test.

The UCLA group is recruiting participants in different stages of glaucoma for the next phase of research in order to provide a more comprehensive look at how glaucoma impacts gait.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Microfluidic chips advance neurodegenerative disease research